2023-08-29 08:06:00 ET
More on Apellis
- Sticking With Apellis: Navigating Syfovre's Safety Measures In A Volatile Market
- Apellis Pharmaceuticals, Inc. ( APLS ) Q2 2023 Earnings Call Transcript
- Apellis Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade)
- Apellis rises 33% on eye drug Syfovre safety update
- Apellis falls as Astellas wins FDA nod for rival product
- Apellis extends selloff as JPMorgan becomes latest to downgrade
For further details see:
Apellis to shed 25% of staff in corporate restructuring